Sort
21,281 grants matching “influenza”
Effect of Virus Infections on the Maintenance of Transplantation Tolerance
$300,012Raymond M Welsh · Univ Of Massachusetts Med Sch Worcester · P01 · FY2012 · AI
Core B: Virology Core
$300,001Sarah M Valencia · Boston Children'S Hospital · P01 · FY2025 · AI
THE VAST GENETIC AND ANTIGENIC VARIABILITY OF VIRUSES LIKE THE PORCINE REPRODUCTIVE AND RESPIRATORY DISEASE SYNDROME VIRUS (PRRSV) AND INFLUENZA POSE A LONG-STANDING CHALLENGE IN THE FIELD OF VACCINOLOGY. THE PHENOMENON OF ANTIBODY BASED IMMUNODOMINANCE, WHEREIN THE INFECTING VIRUS DIRECTS THE IMMUNE SYSTEM TO PRODUCE WASTEFUL RATHER THAN PROTECTIVE ANTIBODY RESPONSES TO ESCAPE HOST IMMUNITY, ALSO SERVES AS A MAJOR CONFOUNDING FACTOR FOR EFFECTIVE VACCINE DEVELOPMENT. FURTHER, THE EARLY UNDERMINING OF THE IMMUNE RESPONSE RESULTS IN THE AMPLIFICATION OF THE SUBOPTIMAL RESPONSE WITH EVERY SUBSEQUENT INFECTION OR BOOSTER VACCINATION, THUS INCREASINGLY DIMINISHING VACCINE EFFICACY AGAINST NEWLY EMERGING VARIANTS WITH AGE.THEREFORE, A MAJOR GOAL OF THIS PROJECT IS TO RATIONALLY RE-ENGINEER THE IMMUNODOMINANCE PATTERNS OF SELECTED PRRSV VACCINE ANTIGENS TO IMPROVE THE QUALITY OF THE ANTIBODY RESPONSE OF PRRSV VACCINES. A SECONDARY GOAL OF THE PROJECT IS TO DEVELOP THE PRRSV VACCINE AS A DELIVERY SYSTEM FOR OTHER SWINE VIRAL VACCINE ANTIGENS, TO REDUCE THE COST AND EFFORT ASSOCIATED WITH VACCINATION. PORCINE CIRCOVIRUS TYPE 3 IS A NEWLY EMERGED SWINE VIRUS WHICH ALSO CAUSES REPRODUCTIVE AND RESPIRATORY DISEASE IN PIGS. IT IS VERY FREQUENTLY CO-DETECTED WITH PRRSV. HENCE, THE RATIONALLY DESIGNED PRRSV VACCINE WILL BE ENGINEERED TO ALSO DELIVER THE PCV3 VACCINE ANTIGEN SIMULTANEOUSLY TO VACCINATED PIGS. TO TEST THE DUAL PRRSV-PCV3 VACCINE, GROUPS OF PIGS WILL BE VACCINATED WITH THE CONSTRUCT, WHILE CONTROL PIGS WILL EITHER REMAIN UNVACCINATED OR RECEIVE A COMMERCIAL VACCINE. AFTER ALLOWING TIME FOR THE DEVELOPMENT OF THE IMMUNE RESPONSE, THE VACCINATED PIGS WILL BE EXPOSED TO PRRSV AND PCV3 VIRUSES. IT IS EXPECTED THAT VACCINATION WILL RESULT IN PROTECTION AGAINST PRRSV DISEASE MANIFESTATIONS AND ELICIT IMPROVED ANTI-PRRSV ANTIBODY RESPONSES, AND THAT VACCINATED PIGS WILL ALSO BE PROTECTED AGAINST PCV3 REPLICATION AND PATHOLOGY. WE EXPECT THAT THE PROJECT OUTCOMES WILL SIGNIFICANTLY IMPROVE PRRSV VACCINE PERFORMANCE, PROVIDE A TEMPLATE FOR IMPROVING CURRENT VACCINES AGAINST GENETICALLY VARIABLE VIRUSES AND DEVELOP THE PRRSV VACCINE AS A DELIVERY SYSTEM FOR MULTIPLE SWINE INFECTIONS.
$300,000North Dakota State University · · FY2025 · National Institute of Food and Agriculture
The First LANCL2-based therapeutic for influenza
$300,000Raquel Hontecillas · Biotherapeutics, Inc. · R43 · FY2021 · AI
Novel Vaccine Immunogens for Pandemic H5 Influenza
$300,000Robert Gerald Whalen · Maxygen, Inc. · R43 · FY2009 · AI
Outpatient VE for seasonal flu, pandemic flu and RSV in a large, diverse network
$300,000Richard K Zimmerman · University Of Pittsburgh At Pittsburgh · U01 · FY2018 · IP
Determining Influenza Vaccine Effectiveness (DIVE)
$300,000Helen Keipp Talbot · Vanderbilt University · U01 · FY2015 · IP
Development of a Non-adjuvanted VLP Vaccine against Stealth H7N9 Influenza
$300,000Anne Searls De Groot · Epivax, Inc. · R43 · FY2016 · AI
siRNA Modulation of the Immune Response
$300,000William C Raschke · Virogenics, Inc. · R43 · FY2013 · AI
DEVELOPING SUSTAINABLE INFLUENZA SURVEILLANCE NETWORKS AND RESPONSE TO AVIAN AND
$300,000Pagbajabyn Nymadawa · Ministry Of Health Mongolia · U51 · FY2012 · IP
Enhanced Surveillance for New Vaccine Preventable Diseases
$300,000Julie Anne Boom · Texas Children'S Hospital · U01 · FY2019 · IP
Gene Gun-delivered RNA vaccines.
$300,000Hannah Frizzell · Orlance, Inc. · R43 · FY2025 · AI
ENHANCING THE INFLUENZA SURVEILLANCE AND CONTROL
$300,000Cojocaru Radu · Ministry Of Health · U51 · FY2013 · IP
Point of care detection of respiratory viruses
$300,000Thomas William Schoenfeld · Lucigen Corporation · R43 · FY2009 · AI
Sustaining Influenza Surveillance Networks and Response to Seasonal
$300,000Ricardo Cortes-Alcala · Fundacion Mexico Estados Unidos/Cienca · U51 · FY2013 · IP
Live-attenuated ETEC Anti-Diarrhea Vaccine Construction via Synthetic Biology
$300,000John Robert Coleman · Codagenix, Inc. · R41 · FY2014 · AI
Evaluating the Impact of Mandatory Influenza Vaccination for Hospital Workers in
$300,000Katherine Marie Harris · Rand Corporation · U01 · FY2011 · IP
Influenza and Other Emerging Infectious Diseases in Vietnam (U01)
$300,000Hien Tran Nguyen · National Institute Hygiene/Epidemiology · U01 · FY2013 · IP
COMBINATION CHEMOTHERAPY FOR PANDEMIC INFLUENZA
$300,000St. Jude Children'S Research Hospital · R21 · FY2005 · AI
Development of a vaccine for prevention of Haemophilus influenzae otitis media
$300,000Stephen J. Barenkamp · Saint Louis University · R01 · FY2011 · AI
Development of a novel highly effective influenza vaccine
$300,000Pamuk Bilsel · Flugen, Inc. · R41 · FY2014 · AI
Adjuvanted Influenza Vaccine
$300,000Peter Blackburn · Mercia Pharma, Inc. · R43 · FY2008 · AI
PREPAREDNESS AND RESPONSE TO AVIAN AND PANDEMIC INFLUENZA IN MADAGASCAR
$300,000Jean-Michel Heraud · Pasteur Institute From Madagascar · U51 · FY2009 · IP
Broadly protective (universal) virus-like particle (VLP) based influenza vaccine
$300,000Jose M Galarza · Technovax, Inc. · R43 · FY2014 · AI
PREPAREDNESS AND RESPONSE TO AVIAN AND PANDEMIC INFLUENZA IN ZAMBIA
$300,000Peter Mwaba · Ministry Of Health Zambia · U51 · FY2010 · IP